Tumor Necrosis Factor Inhibitor Drugs Market Trends

Growth Drivers

• Effectiveness in the management of chronic illnesses: The global tumor necrosis factor inhibitor drugs market is rapidly expanding due to the rising prevalence of autoimmune diseases, including Crohn's disease, psoriasis, ankylosing spondylitis, ulcerative colitis, and rheumatoid arthritis. Tumor necrosis factor (TNF) inhibitors such as Adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol are used for treating these diseases. Moreover, there has been a rising preference for personalized medicine, resulting in growing demand for customized TNF inhibitors. Many pharmaceutical giants are focusing on developing personalized medicines to cater to the rising consumer demand.
• Modern healthcare facilities & quick TNF inhibitor biosimilar deployment: As the global population is steadily aging, companies are focused on providing advanced healthcare facilities and products along with reimbursement policies. This has also resulted in increasing production of medications for chronic illnesses, including, TNF blockers. Over the next few years, there will likely be a global increase in demand for tumor necrosis factor-alpha blockers due to the increased risk of illness associated with an aging population. Throughout the projection period, TNF inhibitor biosimilars are expected to gain market share due to growing patient knowledge of the benefits and increased patient affordability in low-income nations. In July 2023, Choerus announced the launch of YUSIMRY, a biosimilar TNF inhibitor at USD 995 per carton in the U.S.

Challenges

• Increasing launches of alternatives & exorbitant prices of tumor necrosis inhibitor drugs: The high cost of manufacturing tumor necrosis factor drugs and the dearth of R&D projects are expected to prevent the market from expanding. Throughout the forecast period, a growing inclination towards alternative medicines is anticipated to provide a threat to the tumor necrosis factor inhibitor market. The adverse effects of inhibitor medications on patients are expected to restrict the market growth. Numerous adverse effects of TNF inhibition have been noted in clinical research and post-marketing surveillance, including injection site reactions, neutropenia, infusion reactions, and infections.